Professor, Medicine, University of Oklahoma College of Medicine
Rheumatology
Dr. Joan T. Merrill, MD
|
|
Give Review
Joan Merrill practices Rheumatology. She studied medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine She has 3 awards "Oklahoma Magazine", "Top Doctors: New York Metro Area" and "Fellow (FACR)". Joan T. Merrill, MD is also published. She has 92 publications published. The lastest publication: "Sifalimumab, an anti-interferon- monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.'
Publications
- Changes in Antiphospholipid Antibody Titers during Pregnancy: Data from the PROMISSE Study.
- Why, why, why de-Lupus (does so badly in clinical trials).
- Genetic association of CD247 (CD3ζ) with SLE in a large-scale multiethnic study.
- Differential Expression of the Transcription Factor ARID3a in Lupus Patient Hematopoietic Progenitor Cells.
- Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid Arthritis.
- Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.
- The IRF5-TNPO3 association with Systemic lupus erythematosus (SLE) has two components that other autoimmune disorders variably share.
- Disease activity in Lupus correlates with expression of the transcription factor ARID3a.
- Factors associated with damage accrual in patients with Systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Incep...
- American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort.
- Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription.
- How should lupus flares be measured? Deconstruction of the Safety of Estrogen in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity ...
- Pro-inflammatory adaptive cytokines and shed tumor necrosis factor receptors are elevated preceding Systemic lupus erythematosus disease flare.
- End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1.
- Efficacy and safety of abatacept in Lupus nephritis: a twelve-month, randomized, double-blind study.
- Circulating levels of soluble MER in Lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity.
- Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus.
- Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression.
- End-stage kidney disease in African Americans with Lupus nephritis associates with APOL1.
- Treatment of Systemic lupus erythematosus: new therapeutic avenues and blind alleys.
- Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity.
- Top 10 things to know about Lupus activity measures.
- Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry.
- Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from Lupus patients.
- Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study.
- Co-stimulatory molecules as targets for treatment of Lupus.
- Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for Systemic lupus erythematosus in multiple ancestral groups.
- MicroRNA-3148 Modulates Allelic Expression of Toll-Like Receptor 7 Variant Associated with Systemic Lupus Erythematosus.
- Admixture Mapping in Lupus Identifies Multiple Functional Variants within IFIH1 Associated with Apoptosis, Inflammation, and Autoantibody Production.
- Treatment of Systemic lupus erythematosus: a 2012 update.
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with Systemic lupus erythematosus: co...
- Impact of genetic ancestry and socio-demographic status on the clinical expression of Systemic lupus erythematosus in Amerindian-European populations.
- Two independent functional risk haplotypes in TNIP1 are associated with Systemic lupus erythematosus.
- Long-term safety profile of belimumab plus standard therapy in patients with Systemic lupus erythematosus.
- Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and Lupus flare severity.
- Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with Systemic lupus erythematosus.
- Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as Susceptibility Loci for Systemic Lupus Erythematosus in a Large-Scale Multiracial Replication Study.
- A functional haplotype of UBE2L3 confers risk for Systemic lupus erythematosus.
- Evidence for gene-gene epistatic interactions among susceptibility loci for Systemic lupus erythematosus.
- Optimization of current and future therapy for autoimmune diseases.
- B lymphocyte stimulator levels in Systemic lupus erythematosus: Higher circulating levels in African American patients and increased production after influenza vaccina...
- IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with sys...
- Identification of novel genetic susceptibility loci in African American Lupus patients in a candidate gene association study.
- Genetic and physical interaction of the B-cell Systemic lupus erythematosus-associated genes BANK1 and BLK.
- Influenza vaccination responses in human Systemic lupus erythematosus: impact of clinical and demographic features.
- Genome-wide DNA methylation patterns in CD4+ T cells from patients with Systemic lupus erythematosus.
- Ending the 50-Year Drought of FDA Drug Approval for SLE.
- Rituximab: wanted dead or alive...
- Efficacy and safety of rituximab in moderately-to-severely active Systemic lupus erythematosus: the randomized, double-blind, phase II/III Systemic lupus erythematosus...
- The role of genetic variation near interferon-kappa in Systemic lupus erythematosus.
- A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active Systemic lupus erythematosus.
- Novel evidence-based Systemic lupus erythematosus responder index.
- What was wrong and might now go right with clinical trials for Lupus?
- A polymorphism within IL21R confers risk for Systemic lupus erythematosus.
- Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in Lupus nephritis.
- Identification of IRAK1 as a risk gene with critical role in the pathogenesis of Systemic lupus erythematosus.
- High-density genotyping of STAT4 reveals multiple haplotypic associations with Systemic lupus erythematosus in different racial groups.
- Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of Lupus plasma: linking autoimmunity and atherosclerosis.
- Clinical trials for Lupus--are we there yet?
- Biomarkers relevant to atacicept effects in Systemic lupus erythematosus patients.
- Testosterone patches in Systemic lupus erythematosus.
- Topical tacrolimus and pimecrolimus for cutaneous Lupus.
- Is individualized medicine on the horizon for Lupus?
- Antiphospholipid antibodies and the Antiphospholipid syndrome: clinical significance and treatment.
- A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with Systemic lupus erythematosus.
- Antiphospholipid syndrome: what's new in understanding Antiphospholipid antibody-related stroke?
- Do Antiphospholipid antibodies develop for a purpose?
- The prevalence and clinical significance of Antiphospholipid antibodies in rheumatoid arthritis.
- Computer-assisted pattern recognition of autoantibody results.
- Mycophenolate mofetil or intravenous cyclophosphamide for Lupus nephritis.
- DHEA supplementation: the claims in perspective.
- The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in Systemic lupus erythematosus: a randomized trial.
- A Lupus drug and FDA approval.
- Diagnosis of the Antiphospholipid syndrome: how far to go?
- Genetics of Antiphospholipid syndrome.
- Effects of prasterone on disease activity and symptoms in women with active Systemic lupus erythematosus.
- Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with Antiphospholipid syndrome.
- The Antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.
- Cyclosporin A in Antiphospholipid syndrome.
- Mycophenolate mofetil in Antiphospholipid syndrome.
- Etanercept in Antiphospholipid syndrome.
- Rituximab in Antiphospholipid syndrome.
- Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholip...
- Recurrent pregnancy loss with the Antiphospholipid antibody: a systematic review of therapeutic trials.
- Regulation of the vasculature: clues from Lupus.
- Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus.
- Which outcome measures in SLE clinical trials best reflect medical judgment?
- PTPN22 Association in Systemic Lupus Erythematosus (SLE) with Respect to Individual Ancestry and Clinical Sub-Phenotypes.
- Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.
- Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.
- Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe Systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Schools
Joan Sanford I Weill Medical College Of Cornell University
St Lukes Roosevelt Hospital
New York University
Procedures Preformed
- Steroid Injection
Conditions Treated
- Antiphospholipid Syndrome (APS)
- Arthritis
- Cryoglobulinemia
- Fibromyalgia
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- Oklahoma Magazine
- Top Doctors: New York Metro Area
- Fellow (FACR)
Education
-
NYU School of Medicine -
St Luke's-Roosevelt Hospital Center -
Weill Cornell Medical College of Cornell University
Drug Facts
| NPI NUMBER | 1962471813 | |
| NPPES Provider LastName | MERRILL | |
| NPPES Provider FirstName | JOAN | |
| NPPES Provider ZIPCode | 731045005 | |
| NPPES Provider State | OK | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 363.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1962471813 |
| Last Name Of The Provider | MERRILL |
| First Name Of The Provider | JOAN |
| View All |
Similar Doctors
|
|
Dr. Frederick C. Delafield, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine E. Codding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro Gismondi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. M Faisal Khan, MD |
|
|
Dr. Larry G. Willis, MD |
|
|
Dr. Elizabeth S. Taylor-Albert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda Titus, MD
This Doctor is OpenDoctor Recommended.
|